Martínez-Suárez C1, Roben-Aguilar Y2, Reyes-Acosta O3, Garcia-Vega Y4, Vega- Abascal J5, Sánchez-Linares V6, Sotolongo-Díaz D7, Piña-Rodriguez Y8, Fernández-Martori M9, Betancourt-Pérez A10, Jimenez-Lamas M11, Ballester-Caballero Y12, Pérez-Morgado R13, Curbelo-Alonso M14, Molina-Abad A15, Martínez-Borrego R16, Maturell-Peraza J17, Pulido- Garcia L18, López-Pupo N19, Ramírez-Hidalgo Y20, Ramos-Trujillo M21, Fernández-Ramirez I22, Hernández-Colina M23, Perez –Lopez A24, Leon-Garcia Y25, Chaya-Salgado S26, La O-Ayala Y27, Hernández-Rodriguez R2, Duncan-Roberts Y1 and Bello-Rivero I1*
1Department of Clinical Investigations, Center for Genetic Engineering and Biotechnology (CIGB), Cuba
2Production Direction, Center for Genetic Engineering and Biotechnology (CIGB), Cuba
3Promotion and Distribution Direction, Center for Genetic Engineering and Biotechnology (CIGB), Cuba
4Department of Clinical Trial, Center of Molecular Immunology (CIM), Havana, Cuba
5Jose Avila Serrano Polyclinic, Holguin, Cuba
6Center Polyclinic, Santi Spiritus, Cuba
7Department of Dermatology, Antonio Luaces Iraola Hospital, Ciego de Avila, Cuba
8Faustino Perez Hospital, Cuba
9Carlos J. Finlay Polyclinic, Colon, Matanzas, Cuba
10Arnaldo Milian Castro Hospital, Villa Clara, Cuba
11Maria Curi Oncological Hospital, Cuba
12Amalia Simoni Hospital, Camagüey, Cuba
13Department of Maxillofacial Surgery, Antonio Luaces Iraola Hospital, Ciego de Avila, Cuba
14Gustavo Aldereguia Hospital, Cienfuegos, Cuba
15Pablo Noriega Polyclinic, Mayabeque, Cuba
16Comandante Pinares Hospital, San Cristobal, Artemisa, Cuba
17Heroes del Baire Hospital, Island of Youth, Cuba
18Celia Sanchez Manduley Hospital, Manzanillo, Granma, Cuba
19Juan Bruno Zayas Hospital, Santiago de Cuba, Cuba
20Ernesto Guevara Hospital, Las Tunas, Cuba
21Leon Cuervo Rubio Hospital, Pinar del Rio, Cuba
22Agustinho Neto Hospital, Guantánamo, Cuba
23Havana University, Cuba
24Calixto Garcia Hospital, Cuba
25Center of Medical Surgical Investigations (CIMEQ), Cuba
26Salvador Allende Hospital, Cuba
27Manuel Fajardo Hospital, Havana, Cuba
Background: Basal cell carcinoma is the most common type of skin cancer with major impact in health-related quality of life. The use of the formulation based on the combination of IFN-alpha 2b and IFN-gamma (HeberFERON) is an effective alternative in the treatment of basal cell carcinoma, immunogenic tumor, potentially responsible to immunotherapies. The aim of this report is to record, retrospectively, the effect of HeberFERON patients with BCC in the Cuban real word condition.
Methods: This is a retrospectively study of the use of HeberFERON in real world conditions. Eligible patients were adults with histologic diagnosis of single or multiple basal cell carcinoma of any skin phototype, lesions of any size, subtype, location, recurrent or not, with or without specific prior treatments. Adult patients, who signed the informed consent to receive the treatment with HeberFERON, were identified from the data bases. The evaluation of clinical effectiveness was carried out according to RECIST 1.1. Ethical committee of participating institutions approved the study.
Results: In clinical practice evaluated patients the nose was the region of higher frequency of tumors (36.3%) and the nodular clinical subtype was the predominant (45.3%). Clinical response rate differences (p=0.000) were found, with complete response of 61.9%, and partial response of 32.7%; with an overall response rate of 94.2% The HeberFERON exerted a 100% disease control, with no progression reported in 640 treated patients. The best responder tumor subtypes to HeberFERON were the more aggressive tumors, morpheaform with complete response of 72% (overall response=96%), followed by the infiltrative with complete response of 66.7% (overall response =100%). Tumor with larger size and patients with more than four tumors had lesser response to the antitumor effect of HeberFERON.
Conclusion: HeberFERON was highly effective in basal cell carcinomas in real world conditions. In the context of resistance of skin tumors to hedgehog and immune check point inhibitors the combination of IFNs alpha 2b and IFN gamma appears as a plausible therapeutic option for a wide number of basal cell carcinomas.
Basal cell carcinoma; Multiple basal cell carcinomas; Interferon combination
Martínez-Suárez C, Roben-Aguilar Y, Reyes-Acosta O, Garcia-Vega Y, Vega- Abascal J, Sánchez-Linares V, et al. Basal Cell Carcinoma Treated with HeberFERON. A Real World Retrospective Study. Clin Oncol. 2021;6:1872..